The NYT Refutes TrumpRx’s ‘World’s Lowest Prices’ Claim, But the Analysis Misses Key Context

Report on Flovent Pricing Shows How a Law Designed to Lower List Prices Can Boomerang

And the administration is still trying to get Congress to act on MFN legislation, but there’s not much evidence that the effort is working

GSK and Amgen Add Select Meds to TrumpRx, Offering New Angles on the Pharm-to-Table Future

And new insights on past, present, and future Medicare price “negotiations”

The Number of Americans Skipping Scripts Jumped Between 2023 and 2025, KFF Poll Finds

And three more medicines -- Novartis’ Mayzent, Rydapt, and Tabrecta -- have been added to TrumpRx

A New JAMA Paper Finds Hospitals Aren’t Sharing the Savings from Cancer Biosimilars

Three 340B Narratives to Watch: State Medicaid vs. 340B Providers, the Impact of 340B on Smaller Clinics, and What’s Next in STD Loophole Litigation

UCB releases its list- and net-price disclosures for 2025, making it the third company to show net prices continue to fall

CMS Announces Details on Its Plan to Bring Obesity Meds Into Medicare

But the details suggest that the Trump administration may struggle to get the effort off the ground

GSK’s Price Transparency Data Is Out; Net Prices Are Falling

And Novo will book an extra $4 billion in revenue, citing confidence that its 340B contract pharmacy policies are safe from legal challenges

Are Medicines on TrumpRx Seeing a Boost in Prescriptions? The Data Suggests the Answer Is (Mostly) ‘No’

And the reality that MFN may mean poor access in Europe, not lower prices in the U.S., begins to sink in

Lilly Supercharges the ‘Pharm-to-Conference-Table’ Ecosystem, Partnering With 18 Companies to Bring Lower Zepbound Prices to Employers

And a new resource that makes plain the extent -- and variability -- of hospital markups on pharmaceuticals

Sanofi’s Transparency Report Highlights the Continued Growth of Rebates Paid to Payers

And CMS ‘explanations’ for Medicare drug pricing suggest drugmakers and CMS didn’t see eye-to-eye in half of all ‘negotiations’

Pharmacists Say the Rollout of ‘Negotiated’ Prices in Medicare Is Leading to a Cash-Flow Crunch

And CMS extends the deadline for its MFN-in-Medicaid program in an effort to get small- and mid-size companies on board

Four Takeaways from Minnesota’s 340B Transparency Report

And STAT digs into drugmaker annual reports and finds that some MFN deals are not yet finalized

The Trump Administration Is Selling MFN ‘Codification,’ But No One Is Buying

And the government takes pharma’s side in the debate over state regulation of 340B contract pharmacies

The Prediction Markets Were Right: Trump Mentions TrumpRx -- and MFN Codification -- in his Lengthy State of the Union Address

And looking at public comments on how CMS’ GLOBE and GUARD models will harm innovation

Novo Slashes List Prices on Ozempic and Wegovy In an Effort to Improve Affordability for Patients With High-Deductible Health Plans

And the odds that Trump mentions TrumpRx in his State of the Union speech are at 88% and rising

Comments Are Due Today on the Administration’s Proposed Pilot Programs to Bring MFN Into Medicare

And 340B warps everything ... even local property taxes

Americans Love the Idea of a Website That Offers Cash-Pay Discounts. But They Like It Less When It’s Called ‘TrumpRx.’

Moving to MFN Means QALYs -- Long Rejected by U.S. Policymakers as Discriminatory -- Would Be Used to Set Prices

Plus a look at all the MFN action, from the industry reactions to Democratic positioning to the administration’s sales efforts

Oz Continues to Press for MFN ‘Codification’ at PhRMA Event

The industry's reaction to the call for permanent price controls: 'We’ve seen this movie before'

Going Deeper on Another 'Pharm-to-Conference-Table' Obesity Offering

There are references today to Tom Brady, Mark Cuban, and PBM concentration. Something for everyone!

The Government Is Looking for 340B Rebate Model Feedback As It Resurrects Rulemaking

And PCMA has picked up the pace of its communications, so Cost Curve is going to have to pick up the pace of its fact-checking

Big Pharma Companies Won Concessions via Dealmaking With Trump. But What Happens to Everyone Else?

Big Pharma Companies Won Concessions via Dealmaking With Trump. But What Happens to Everyone Else?

Plus obesity news on adherence, vials, and reimbursement in Medicare

Pfizer Cut the Price of Certain Forms of Ibrance, Its Blockbuster Breast Cancer Med

And a survey of community oncologists finds near unanimity on the negative impacts of step therapy